Sunday, October 13, 2019 2:23:28 PM
I'm never a fan of these analyst reports, but as long as it's higher than today's PPS, I am good with them 
Brokerages Set Aphria Inc (NYSE:APHA) PT at $14.75
Posted by Carol Hyndes on Oct 12th, 2019
https://slatersentinel.com/news/2019/10/12/brokerages-set-aphria-inc-nyseapha-pt-at-14-75.html
Shares of Aphria Inc (NYSE:APHA) have been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $14.75.
APHA has been the subject of a number of recent analyst reports. ValuEngine raised Aphria from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. CIBC cut Aphria from a “neutral” rating to a “sector underperform” rating in a report on Friday, July 26th. Finally, Zacks Investment Research cut Aphria from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 22nd.
Aphria stock opened at $5.64 on Tuesday. Aphria has a one year low of $3.75 and a one year high of $16.19. The business has a 50 day simple moving average of $6.41 and a 200 day simple moving average of $7.29.
Aphria (NYSE:APHA) last posted its earnings results on Thursday, August 1st. The company reported $0.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.10. The company had revenue of $128.60 million for the quarter, compared to the consensus estimate of $99.26 million. The business’s revenue was up 971.7% on a year-over-year basis. On average, equities research analysts forecast that Aphria will post 0.08 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. ETF Managers Group LLC acquired a new stake in Aphria during the 2nd quarter valued at $48,941,000. Vanguard Group Inc. increased its holdings in Aphria by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 5,402,302 shares of the company’s stock valued at $37,870,000 after purchasing an additional 135,714 shares in the last quarter. Bank of America Corp DE increased its holdings in Aphria by 410.2% during the 2nd quarter. Bank of America Corp DE now owns 507,034 shares of the company’s stock valued at $3,554,000 after purchasing an additional 407,658 shares in the last quarter. Swiss National Bank increased its stake in shares of Aphria by 8.0% in the 2nd quarter. Swiss National Bank now owns 445,400 shares of the company’s stock valued at $3,132,000 after buying an additional 33,000 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp acquired a new stake in shares of Aphria in the 1st quarter valued at $4,741,000. 10.98% of the stock is owned by hedge funds and other institutional investors.
About Aphria
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Brokerages Set Aphria Inc (NYSE:APHA) PT at $14.75
Posted by Carol Hyndes on Oct 12th, 2019
https://slatersentinel.com/news/2019/10/12/brokerages-set-aphria-inc-nyseapha-pt-at-14-75.html
Shares of Aphria Inc (NYSE:APHA) have been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $14.75.
APHA has been the subject of a number of recent analyst reports. ValuEngine raised Aphria from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. CIBC cut Aphria from a “neutral” rating to a “sector underperform” rating in a report on Friday, July 26th. Finally, Zacks Investment Research cut Aphria from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 22nd.
Aphria stock opened at $5.64 on Tuesday. Aphria has a one year low of $3.75 and a one year high of $16.19. The business has a 50 day simple moving average of $6.41 and a 200 day simple moving average of $7.29.
Aphria (NYSE:APHA) last posted its earnings results on Thursday, August 1st. The company reported $0.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.10. The company had revenue of $128.60 million for the quarter, compared to the consensus estimate of $99.26 million. The business’s revenue was up 971.7% on a year-over-year basis. On average, equities research analysts forecast that Aphria will post 0.08 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. ETF Managers Group LLC acquired a new stake in Aphria during the 2nd quarter valued at $48,941,000. Vanguard Group Inc. increased its holdings in Aphria by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 5,402,302 shares of the company’s stock valued at $37,870,000 after purchasing an additional 135,714 shares in the last quarter. Bank of America Corp DE increased its holdings in Aphria by 410.2% during the 2nd quarter. Bank of America Corp DE now owns 507,034 shares of the company’s stock valued at $3,554,000 after purchasing an additional 407,658 shares in the last quarter. Swiss National Bank increased its stake in shares of Aphria by 8.0% in the 2nd quarter. Swiss National Bank now owns 445,400 shares of the company’s stock valued at $3,132,000 after buying an additional 33,000 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp acquired a new stake in shares of Aphria in the 1st quarter valued at $4,741,000. 10.98% of the stock is owned by hedge funds and other institutional investors.
About Aphria
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
